Incidence of febrile neutropenia with commonly used chemotherapy regimen in localized breast cancer
Open Access
- 1 January 2020
- journal article
- research article
- Published by Scientific Scholar in South Asian Journal of Cancer
- Vol. 09 (01) , 04-06
Abstract
Introduction: Breast cancer is the most frequently diagnosed cancer among the women. Most commonly used chemotherapy regimen is Doxorubicin and Cyclophosphamide (AC) which carries significant risk of febrile neutropenia. The aim of the study is to identify the incidence of febrile neutropenia and its effects on the delivery of chemotherapy in patients receiving following AC chemoregimen without primary prophylaxis. Materials and Methods: We retrospectively analyzed the case records of the localized breast cancer patients who were treated with AC chemoregimen without primary prophylaxis for febrile neutropenia. Results: Between 2013 and 2017, a total of 231 cases received AC chemoregimen. A total of 14 (6.1%) patients were found to have febrile neutropenia. All patients were recovered by day 19 and no deaths were observed. Except for ECOG performance status (P = 0.001) no significant association was found with age, co-morbidities, menopausal status, body surface area and stage of the cancer. There were no treatment delays or dose reductions because of febrile neutropenia. Conclusion: The incidence of FN with AC chemotherapy in breast cancer patients is relatively less in the present study. Routine primary prophylaxis is not recommended as this chemotherapy falls in to low risk category for FN but can be considered for patients with ECOG PS > 1. If the diagnosis of febrile neutropenia and institution of appropriate measures are prompt, FN did not affect the delivery of chemotherapy and thus compromise survival.Keywords
This publication has 16 references indexed in Scilit:
- Recommendations for genetic testing to reduce the incidence of anthracycline‐induced cardiotoxicityBritish Journal of Clinical Pharmacology, 2016
- Incidence of Febrile Neutropenia in Korean Female Breast Cancer Patients Receiving Preoperative or Postoperative Doxorubicin/Cyclophosphamide Followed by Docetaxel ChemotherapyJournal of Breast Cancer, 2016
- G‐CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF useCancer Medicine, 2014
- Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic reviewCritical Reviews in Oncology/Hematology, 2014
- Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapySupportive Care in Cancer, 2011
- Cancer Pharmacoethnicity: Ethnic Differences in Susceptibility to the Effects of ChemotherapyClinical Cancer Research, 2009
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsCancer, 2006
- Doxorubicin With Cyclophosphamide Followed by Docetaxel Every 21 Days Compared With Doxorubicin and Docetaxel Every 14 Days As Preoperative Treatment in Operable Breast Cancer: The GEPARDUO Study of the German Breast GroupJournal of Clinical Oncology, 2005
- Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741Journal of Clinical Oncology, 2003
- Dose-Response Effect of Adjuvant Chemotherapy in Breast CancerNew England Journal of Medicine, 1981